Equities

Merus NV

Merus NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)14.97
  • Today's Change-0.20 / -1.32%
  • Shares traded445.34k
  • 1 Year change-42.22%
  • Beta0.8170
Data delayed at least 15 minutes, as of Dec 02 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

  • Revenue in USD (TTM)45.63m
  • Net income in USD-63.64m
  • Incorporated2003
  • Employees121.00
  • Location
    Merus NVYalelaan 62UTRECHT 3584 CMNetherlandsNLD
  • Phone+31 302538800
  • Websitehttps://merus.nl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mersana Therapeutics Inc11.90m-208.27m675.47m169.00--7.40--56.74-2.43-2.430.13790.91530.0447----70,437.87-78.23-52.20-104.23-70.47-----1,749.59-547.25---89.590.216---94.81-72.04-93.15---9.78--
ANI Pharmaceuticals Inc283.08m-69.20m678.50m601.00--2.18--2.40-4.48-4.4818.0019.260.46811.732.29471,018.30-11.21-1.35-13.00-1.6451.8360.08-23.95-3.092.62-2.160.4599--3.6710.94-89.79---10.95--
Repare Therapeutics Inc120.51m-25.68m680.20m168.00--2.22--5.64-0.7351-0.73512.877.290.342--1.00792,822.40-7.29---8.29-------21.31------0.00--5,529.63---100.14------
Tango Therapeutics Inc24.17m-101.16m681.61m109.00--2.49--28.21-1.15-1.150.27493.100.0486--4.83265,549.40-20.35---22.46-------418.63------0.00-------47,226.29------
SNDL Inc368.16m-196.77m682.08m184.00--0.6355--1.85-0.8718-0.87181.664.530.30234.1331.892,000,864.00-16.24---17.29--22.42---53.71--4.78-0.37330.1476---7.86---15.41------
Anavex Life Sciences Corp0.00-47.98m691.52m38.00--4.85-----0.6231-0.62310.001.830.00----0.00-30.53-46.07-32.71-51.22------------0.00-------26.56------
Editas Medicine Inc25.64m-201.13m691.76m264.00--1.67--26.98-2.93-2.930.37416.030.0411--138.2497,136.37-32.23-28.88-34.83-32.06-----784.32-368.55----0.00---71.8533.37-65.98--17.96--
Alector Inc133.17m-133.96m698.00m269.00--2.76--5.24-1.63-1.661.623.060.1575--32.98640,245.20-15.84-22.06-19.17-25.83-----100.59-148.38----0.00--881.54246.2780.90--7.61--
Merus NV45.63m-63.64m702.41m121.00--2.35--15.39-1.45-1.451.056.450.1184--15.56377,099.20-16.51-24.71-20.04-29.16-----139.48-178.24----0.00--64.0077.6421.86--9.66--
Allovir Inc0.00-188.52m706.18m107.00--2.77-----2.79-2.790.002.730.00----0.00-61.79---66.69--------------0.00-------146.42------
Allakos Inc0.00-371.33m707.19m192.00--2.05-----6.76-6.760.004.040.00----0.00-71.43-32.18-76.45-33.39------------0.00-------75.83--169.43--
Exscientia PLC (ADR)43.98m-84.95m709.01m287.00--1.08--16.12-0.7015-0.70150.3655.350.0741--81.49153,251.50-14.32---15.98--32.57---193.15--9.08--0.0123--182.87---120.94------
POINT Biopharma Global Inc0.00-79.17m709.93m72.00--2.26-----0.8713-0.87130.002.970.00----0.00-26.26---27.39--------------0.00-------243.25------
Aurinia Pharmaceuticals Inc129.00m-115.46m720.50m300.00--1.70--5.59-0.8297-0.82970.92392.980.30410.21445.00429,996.70-27.22-35.60-30.03-37.8196.29---89.50-523.0310.40--0.00---9.00204.93-76.24--126.82--
Invitae Corp519.97m-3.21bn721.40m2.30k--4.54--1.39-13.84-13.842.250.65420.146513.897.05173,323.30-90.50-19.73-94.07-20.7519.1332.19-617.65-121.686.18-14.590.9096--64.6879.0137.06--36.32--
Theravance Biopharma Inc51.64m-82.19m727.55m158.00--1.51--14.09-1.1011.250.68627.130.0885--3.67326,854.40-14.09-50.90-17.15-62.74-----159.16-439.62----0.00---23.032.6028.27--9.79--
Data as of Dec 02 2022. Currency figures normalised to Merus NV's reporting currency: US Dollar USD

Institutional shareholders

42.38%Per cent of shares held by top holders
HolderShares% Held
Federated Global Investment Management Corp.as of 30 Sep 20223.60m7.84%
BVF Partners LPas of 30 Sep 20223.44m7.51%
Commodore Capital LPas of 30 Sep 20222.62m5.70%
Deerfield Management Co. LPas of 30 Sep 20222.52m5.50%
Wellington Management Co. LLPas of 30 Sep 20221.94m4.22%
Aquilo Capital Management LLCas of 30 Sep 20221.51m3.29%
Driehaus Capital Management LLCas of 30 Sep 20221.10m2.40%
Woodline Partners LPas of 30 Sep 20221.05m2.29%
Franklin Advisers, Inc.as of 30 Sep 20221.05m2.28%
Samlyn Capital LLCas of 30 Sep 2022617.65k1.35%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.